CVAC Key Statistics, Chart & Performance
The current stock price of CVAC is 5.2 USD. In the past month the price decreased by -2.62%. In the past year, price increased by 67.74%.
CVAC Latest News, Press Relases and Analysis
CVAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About CVAC
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Franz-Werner Haas
Employees: 904
Phone: 49707198830
CUREVAC NV / CVAC FAQ
Can you describe the business of CUREVAC NV?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
What is the stock price of CUREVAC NV today?
The current stock price of CVAC is 5.2 USD. The price decreased by -5.28% in the last trading session.
What is the dividend status of CUREVAC NV?
CVAC does not pay a dividend.
What is the ChartMill rating of CUREVAC NV stock?
CVAC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is CVAC stock listed?
CVAC stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for CUREVAC NV?
CUREVAC NV (CVAC) operates in the Health Care sector and the Biotechnology industry.
Should I buy CVAC stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CVAC.
CVAC Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CVAC. When comparing the yearly performance of all stocks, CVAC is one of the better performing stocks in the market, outperforming 90.57% of all stocks.
CVAC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CVAC. CVAC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
CVAC Financial Highlights
Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of 1.01. The EPS increased by 170.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.93% | ||
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| Debt/Equity | 0.05 |
CVAC Forecast & Estimates
13 analysts have analysed CVAC and the average price target is 4.78 USD. This implies a price decrease of -8.12% is expected in the next year compared to the current price of 5.2.
For the next year, analysts expect an EPS growth of -170.56% and a revenue growth -86.75% for CVAC